Metabolic syndrome in obese children born large for gestational age

Xiumin Wang1, Li Liang, F U Junfen

  • 1Department of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.

Insights

Obese children born large-for-gestational age (LGA) have a higher prevalence of metabolic syndrome (MS) and associated conditions like hypertension and hypertriglyceridemia compared to appropriate-for-gestational age (AGA) peers. Early adiposity rebound is also linked to MS risk in these children.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Health

Background:

  • Metabolic syndrome (MS) is a growing concern in pediatric populations.
  • Large-for-gestational age (LGA) birth status may influence long-term metabolic health.
  • Understanding these associations is crucial for early intervention.

Purpose of the Study:

  • To compare the prevalence of metabolic syndrome (MS) and insulin release in Chinese obese children born large-for-gestational age (LGA) versus appropriate-for-gestational age (AGA).
  • To investigate the relationship between birth weight status and metabolic health markers in obese children.

Main Methods:

  • A comparative study involving obese children categorized into LGA (n=60) and AGA (n=312) groups.
  • Clinical and metabolic characteristics were assessed, including an oral glucose tolerance test to measure glucose and insulin levels.
  • Prevalence of MS and its components were determined and compared between groups.

Main Results:

  • Obese children born LGA exhibited an earlier age of adiposity rebound (AR) compared to AGA counterparts.
  • The prevalence of MS was significantly higher in the LGA group (65%) than in the AGA group (42.3%).
  • LGA status independently increased the risk for MS, hypertension, and hypertriglyceridemia; earlier AR was linked to hypertriglyceridemia.

Conclusions:

  • Obese children born LGA demonstrate a higher prevalence of metabolic syndrome, hypertension, and hypertriglyceridemia.
  • An earlier age of adiposity rebound is associated with increased metabolic risk in this population.
  • Hypertension and hypertriglyceridemia are key indicators for diagnosing MS in obese children.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...